Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm targets Nasdaq Listing by end of 2024

Friday, July 26, 2024 1 min read
Key Takeaway: Radiopharm Theranostics is aiming for a Nasdaq listing by the end of 2024. The company has made significant progress, including receiving IND approval from the US FDA for a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, Radiopharm has reported positive clinical updates across four of its programs, indicating a strong pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm is targeting a Nasdaq listing by the end of 2024.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• July 26, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• December 6, 2022
• Updates
• September 6, 2024
• Announcements
• April 27, 2023
• Announcements
• March 17, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is Radiopharm's target for Nasdaq?

Radiopharm is targeting a Nasdaq listing by the end of 2024.

What recent approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA for a Phase I study.

What clinical updates has Radiopharm provided?

Radiopharm has reported positive updates across four of its clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Nasdaq FDA approval clinical updates
Last updated: Jul 26, 2024